52 results about "Foam cell" patented technology

The invention provides a preparation method of an ADC foaming agent for improving foaming pore density, which comprises the following steps: step 1, mixing a modified inorganic nucleating agent with water according to a predetermined mass ratio, adding a dispersing agent, and uniformly mixing to prepare uniform and stable suspension slurry to prevent agglomeration of the nucleating agent; 2, when the conversion rate of the biurea reaches 80%-85%, adding the suspension slurry, so that the inorganic nucleating agent is uniformly attached to the surface of the ADC crystal; and 3, continuing the oxidation reaction until the biurea conversion rate reaches 92% or above, and then washing, centrifuging and drying to obtain the ADC foaming agent. The ADC foaming agent for improving the foaming pore density is prepared by the method. The inorganic nucleating agent is added in the stage of preparing the ADC foaming agent, and compared with the inorganic nucleating agent added in the subsequent foam material preparation process, the density of foaming pores can be remarkably improved.

Provided are a metal-organic framework nanomaterial, a preparation method therefor, and a use thereof, belonging to the technical field of bionanomaterials, and resolving the technical problem of inhibiting atherosclerosis using biomimetic metal-organic framework nanoenzymes. The solution is: the components of the of the metal-organic framework nanomaterial and the ratio thereof are: metal ions Ce4+ and a ligand fumaric acid in a molar ratio of 1:5. The preparation method therefor is: measuring an FA regulator and water to prepare a mixed solution, then adding fumaric acid and cerium ammonium nitrate dropwise into the mixed solution, stirring at room temperature, centrifuging, repeatedly washing alternately with water and ethanol, and finally drying overnight in a vacuum oven. A simple, efficient and convenient method for synthesizing the metal-organic framework nanomaterial is provided. The synthesized metal-organic framework nanomaterial has excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be used to increase lipid efflux and reduce lipid uptake, and decrease ox-LDL-induced foam cell formation, thereby alleviating atherosclerosis.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

The application discloses a preparation process of a secondary foaming type water-based synthetic leather and relates to the technical field of high polymer foaming materials.The preparation process comprises the following steps: 1) epoxy modification of thermal expansion microspheres;2) side chain amino modification of polyurethane;3) preparation of foaming slurry;4) preparation of synthetic leather;firstly, the thermal expansion microspheres are subjected to epoxidation, the water-based polyurethane is grafted with side chain amino groups protected by tert-butyloxycarbonyl, and the crosslinking degree is improved by using triphenylmethane triisocyanate, and then the thermal expansion microspheres are mixed with the epoxy modified thermal expansion microspheres;after the first foaming by mechanical means, the tert-butyloxycarbonyl is dissociated to generate CO2 gas under heat in the step 4), active amino groups are released, crosslinked with the epoxy of the thermal expansion microspheres, and the thermal expansion microspheres are expanded at the same time, so that chemical foaming, namely the second foaming, is realized.The mechanical and chemical secondary foaming process is used in cooperation, the pain points of the traditional water-based leather, such as hard hand feeling, easy collapse of foaming cells and single performance, are solved, and the comprehensive performance is obviously improved compared with the prior art.

This invention relates to the field of natural product chemistry, specifically to the application of a *Syzygium brevicornum* leaf extract in the preparation of drugs for the prevention and / or treatment of atherosclerosis. The preparation method of the *Syzygium brevicornum* leaf extract of this invention includes the following steps: taking dried *Syzygium brevicornum* leaves, extracting with ethanol solution, filtering, combining the extracts, and concentrating under reduced pressure to obtain a total extract of *Syzygium brevicornum* leaf ethanol extract; extracting the total extract of *Syzygium brevicornum* leaf ethanol extract with ethyl acetate to obtain the *Syzygium brevicornum* leaf extract. Using the RAW264.7 foam cell model, this invention found that the *Syzygium brevicornum* leaf extract prepared by this invention can reduce lipid accumulation in RAW264.7 macrophage-derived foam cells, suggesting that the *Syzygium brevicornum* leaf extract prepared by this invention can be used to prepare drugs for the prevention and / or treatment of atherosclerosis.

The invention relates to the technical field of specific therapeutic activity of pharmaceutical preparations, in particular to application of Avasimibe in preparation of drugs for treating pulmonary fibrosis. The invention relates to an application of Avasimibe in preparation of a medicine for treating pulmonary fibrosis. The Avasimibe is used for reducing the generation of foam cells by targeting SOAT1 so as to relieve the occurrence and development of pulmonary fibrosis. The invention reveals that Avasimibe can reduce the generation of foam cells by targeting SOAT1 so as to relieve the occurrence and development of pulmonary fibrosis. Meanwhile, it is also elaborated that Avasimibe can restore the steady state of cholesterol and cholesteryl ester, improve the fluidity of a cell membrane structure and restore the lipophagy function, and the invention develops the application of Avasimibe in treatment of pulmonary fibrosis diseases.

The present application discloses foamable compositions comprising cellulose acetate and a combination of a carbon dioxide as a physical blowing agent and a chemical blowing agent. The foamable compositions are used to prepare foams that exhibit lower density, lower average foam cell size, and fewer corrugations than foams made only by carbon dioxide.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

The application discloses a novel polyphenyl ether / polystyrene foaming bead with a nested structure and a preparation method thereof, and belongs to the technical field of microporous foaming of high polymer materials. The raw material of the polyphenyl ether / polystyrene foaming bead comprises the following components in percentage by mass: 40-85% of polystyrene, 5-40% of polyphenyl ether, 5-20% of polypropylene, 0.1-5% of an inhomogeneous nucleating agent, 0.5-1.2% of an antioxidant and 0.1-0.3% of a dispersing agent. The application optimizes the raw material, adds polytetrafluoroethylene to increase the adsorption effect of the material on a foaming agent, and realizes the redesign of a foaming cell structure by using the sea-island structure of the polypropylene in the polyphenyl ether / polystyrene matrix after foaming, so that the foaming cell with a polypropylene film inside and a polyphenyl ether / polystyrene structure outside is obtained, the foaming temperature required for the polyphenyl ether foaming bead is reduced, and the problem of high foaming temperature of the polyphenyl ether foaming bead in the prior art is solved.

The utility model relates to the technical field of elastomers, in particular to a supercritical foaming elastomer drying device which comprises a shell, the shell comprises a feeding pipe, a transmission frame, a screen frame, a motor, a transmission structure and a discharging pipe, the feeding pipe is fixed to the top end of the shell, the transmission frame is fixedly connected to the inner top end of the shell, and the motor is fixedly connected to the bottom end of the shell. Through sieving, uneven heating or local degradation during drying can be avoided, and the material purity is guaranteed; for the high-hygroscopicity elastomer, the subsequent foaming defect caused by impurity adsorption can be reduced through sieving; the particle uniformity is optimized, elastomer particles with uniform particle sizes can be screened out through screening, it is ensured that the heat transfer efficiency and the moisture escape efficiency are consistent in the drying process, and the drying effect is improved; the uniform particles are easier to form a stable gas saturation state in the supercritical fluid, so that the uniformity of subsequent foaming cells is facilitated.

The invention discloses a high-impact-resistance flame-retardant foaming diffusion plate and a preparation method thereof.The preparation method comprises the steps that SBS-g-GMA is prepared, polyimide microspheres are prepared, GPPS resin, SBS-g-GMA, polyimide microspheres, an ultraviolet light absorber and other components are mixed to be uniform, melt extrusion molding is conducted, and the like. According to the present invention, the haze is 90-95%, the center brightness achieves more than 2000, the average brightness achieves more than 1600, the impact strength achieves more than 10 Kg-cm / cm, the flame retardation achieves the V0 level, the pores are fine and uniform, the cost is saved, the optical performance is ensured, and the effects of light weight, high impact resistance and high flame retardation are achieved.

This invention discloses a method for preparing filler particles for targeted adsorption of low-density lipoprotein (LDL) in patients with atherosclerosis. The steps include: 1) washing D101 macroporous resin with ultrapure water and physiological saline; 2) adding fibrin and PBS solution for soaking; adding thrombin factor II; adding zinc gluconate during the reaction; 3) repeating step 2) at least three times and drying the D101 macroporous resin; 4) adding physiological saline and D101 macroporous resin to lyophilized protein ApoB100 and mixing thoroughly; 5) lyophilizing the resin obtained in step 4) while controlling the humidity at 65±5% to obtain the finished product. This application utilizes this adhesion effect to target the adsorption of foam cells in atherosclerosis, adsorbing foam cells through hemoperfusion, removing redundant blood lipid components in the body, reducing macrophage infiltration of organs and blood vessels, and reducing pathological changes in organs and blood vessels.

A method for preparing a bifunctional foam featuring "high strength / high energy absorption" and "super-hydrophobicity / self-cleaning", relating to the technical field of organic polymer materials. By means of a gas foaming technology, composite constraint is used to introduce anisotropic foam cells into a polymer material, and the anisotropic foam cells endow the polymer material with super energy absorption characteristics by means of unique deformation of progressive buckling and reciprocating distortion under compression or impact; and a "barbed" structure is introduced onto the surface of the polymer, achieving the super-hydrophobic / self-cleaning function on the surface of the polymer foam, and finally obtaining a bifunctional polymer foam featuring "high strength / high energy absorption" and "super-hydrophobicity / self-cleaning". The method is simple, feasible, and environmentally friendly, has low cost and good reproducibility, and can achieve large-scale production. The resulting thermoplastic polymer material, such as a polypropylene foam, has excellent performance and important significance in the field of safety protection.

The invention provides a supercritical nitrogen high-temperature and high-pressure silica gel foaming device and a material thereof, and relates to the technical field of methyl vinyl silicone rubber. Supercritical nitrogen is adopted to replace a chemical foaming agent, a core process link of pre-crosslinking curing is realized through silica gel foaming UV ultraviolet radiation process parameters, and a parameter system is based on a photoinitiator system and depends on a UV-A wave band light source; by accurately controlling the irradiation dose, high-efficiency and low-heat-damage industrial production extrusion molding, segmented swelling, three-section type pressure reduction and secondary segmented crosslinking processes are realized, and the problems of non-uniform cells, chemical residues and the like in a traditional method are solved. According to the silicone rubber with the process adaptive density of 100-200 kg / m < 3 >, different process parameters are adopted according to different densities, nano calcium carbonate is added to serve as a nucleating agent, the product performance is excellent, and the silicone rubber can be applied to the high-end fields such as 5G chip cushions and aerospace damping liners and has high economic value and good application prospects.

The application belongs to the technical field of biological medicine, and particularly relates to a kind of nano-lipid granules for treating atherosclerosis and its preparation method and application, the nano-lipid granules take PLGA encapsulated PDHA1 protein and aggregation-induced emission molecule as core, foam cell membrane is coated on the surface of PLGA, the outermost layer is coated with active oxygen responsive liposome;Aggregation-induced emission molecule is the coupling product of diphenylamine donor unit and benzothiadiazole-thiophene acceptor unit.The present application co-delivers PDHA1 protein and AIE photothermal molecule, homologous targeting of foam cell membrane, active oxygen responsive liposome outer layer and near-infrared two-zone imaging / photothermal therapy function is integrated in a single nano platform, realizes the precise diagnosis of HHcy-AS, metabolic microenvironment repair and photothermal removal of foam cells multimodal synergistic therapy, and provides a new treatment strategy for atherosclerosis, especially high homocysteine related atherosclerosis.

The invention provides a preparation method and application of a multi-target enzymatic self-assembly fluorescence activated nanoprobe, and belongs to the field of pharmacy. According to the method, an Fmoc solid-phase peptide synthesis strategy is adopted, an N end is connected with a fluorescence quencher Dabcyl, a C end is marked with fluorescein, a near C end is a self-assembly sequence Y (pY) YG capable of generating self-assembly behavior through dephosphorylation of alkaline phosphatase, and a middle section is a cleavage sequence KGGFLGK capable of being cleaved into a fluorescent'switch 'by cathepsin B; the near N end is a functional polypeptide F-pY-LyP-1 of a targeting sequence CGNKRTRGC or LyP-1 which can be highly combined with a p32 receptor on the surface of a foam cell. The fluorescence activated nanoprobe accurately reaches a plaque part under the synergistic effect of multiple target points and is self-assembled into spherical nanoparticles, so that the aggregation and retention effects of the probe in the plaque are improved, the non-specific signal interference is reduced, and the early atherosclerotic plaque is more accurately identified.

A metal-organic framework (MOF) nanomaterial, its preparation method, and its application belong to the field of bionanomaterials technology. It addresses the technical problem of inhibiting atherosclerosis using biomimetic nanoenzymes derived from metal-organic frameworks. The solution involves the composition and proportion of the MOF nanomaterial as follows: [The remaining text appears to be incomplete and requires further context for accurate translation.] 4+ The molar ratio of ions to fumaric acid ligand is 5:1. The preparation method is as follows: a mixed solution is prepared by measuring FA regulator and water; then fumaric acid and cerium ammonium nitrate are added dropwise to the mixed solution; the mixture is stirred at room temperature and centrifuged; the solution is washed repeatedly with alternating water and ethanol; and finally, it is dried overnight in a vacuum oven. This invention provides a simple, efficient, and convenient method for synthesizing MOF nanomaterials. The synthesized MOF nanomaterials possess excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be applied to increase lipid efflux and reduce lipid uptake, decrease ox-LDL-induced foam cell formation, and thus alleviate atherosclerosis.

The invention discloses an application of MLN4924 and flubendazole in preparation of a medicine for treating atherosclerosis. The MLN4924 and the flubendazole which are low in dosage almost have no cytotoxicity and can be used for treating atherosclerosis by intervening foam cell formation and cholesterol accumulation, and the MLN4924 and the flubendazole are combined for use, so that the effect is stronger, and synergistic interaction is realized.

The present invention discloses a hydrophobic microporous urea-formaldehyde foam material and a preparation method thereof, which belong to the field of polymer chemical modification. The preparation of the above-mentioned urea-formaldehyde foam material includes the following raw materials: urea-formaldehyde resin modified by amphiphilic macromolecules, a foaming agent and a curing agent, the amphiphilic macromolecules including a hydrophilic end and a hydrophobic end, the hydrophilic end is used for reaction connection with the urea-formaldehyde resin, and the hydrophobic end is used for reaction connection with the foaming agent. The present invention connects the amphiphilic macromolecule bond to the urea-formaldehyde molecular network, so that it self-assembles in the urea-formaldehyde water-based system to form a micro-nano assembly structure with rich morphology; adjusts the affinity of the foaming agent and the hydrophobic chain segments in the assembly structure, induces the foaming agent to be dispersed in the hydrophobic chain segment aggregates of the assembly, and simultaneously regulates the foaming and curing process, restricts the nucleation and growth of the foam cells and fixes them inside or around the hydrophobic chain segment aggregates of the micro-nano assembly, exerts the strong hydrophobic coating effect of the hydrophobic chain segments on the bubble wall, gives the urea-formaldehyde foam a long-lasting hydrophobic function, and realizes the construction of a microporous structure.

This invention relates to the field of cardiovascular disease research technology, and particularly to the application of the NOD1 inhibitor ML130 in hypoxia-induced macrophage polarization, including the use of ML130 in the preparation of drugs that regulate hypoxia-induced macrophage polarization. These drugs inhibit the NOD1 / RIP2 signaling axis and can be used to intervene in the formation and progression of atherosclerotic plaques. This invention creatively combines the NOD1 inhibitor ML130 with the hypoxic microenvironment of atherosclerotic plaques, specifically inhibiting the NOD1 / RIP2 signaling pathway and directly regulating macrophage polarization balance; reducing the accumulation of pro-inflammatory cells in unstable plaque areas, inhibiting foam cell formation and necrotic core expansion, significantly improving plaque stability, and reducing the risk of serious cardiovascular events such as acute coronary syndrome; it clarifies that ML130 exerts its effect by blocking the NOD1 / RIP2-NF-κB / MAPK signaling axis, exhibiting high target specificity and avoiding the side effects of broad-spectrum inhibition by traditional anti-inflammatory drugs.

To provide a molded component of uneven thickness that is lightweight yet has excellent strength and appearance.　A molded component 1 is made of a thermoplastic resin and comprises a base 2 and first ribs 6. The base 2 has a thin part 3, a thick part 4, and a step part 5 formed between the thin part 3 and the thick part 4. The first ribs 6 protrude from one surface 3a of the thin part 3 in the thickness direction of the thin part 3 and contact the step part 5. The ratio of foam cells in the thin part 3 is 0-5%. The ratio of foam cells in the thick part 4 is 5-50%. A width W of the base of the first ribs 6 is 1.0 times or more the average thickness t1 of the thin part 3. The ratio of the foam cells in the first ribs 6 is from more than 0% to 90%.

The invention relates to the technical field of cell targeted therapy, in particular to a construction method of OPN-targeted chimeric antigen receptor mononuclear macrophages and application of the OPN-targeted chimeric antigen receptor mononuclear macrophages to removal of foam cells. The chimeric antigen receptor mononuclear macrophage targeting OPN is a mononuclear macrophage of which a cell membrane is integrated with a chimeric antigen receptor of which the nucleotide sequence is as shown in SEQ ID NO.7. The invention further discloses a preparation method of the chimeric antigen receptor mononuclear macrophage. Different from a technical path of only targeting membrane protein in a traditional CAR therapy, the method innovatively selects secreted protein OPN as a target spot, and realizes accurate recognition and efficient removal. The strategy breaks through the technical prejudice that secreted protein cannot be used as an effective CAR target spot, formed foam cells can be directly removed, and the lesion process is reversed. According to the technical scheme, the technical problem that a safe and effective method for removing foam cells is lacked in the prior art can be solved, and the traditional Chinese medicine composition is remarkably superior to an existing lipid-lowering or anti-inflammatory therapy and has an outstanding treatment effect and a wide clinical application prospect.

The invention discloses a nocardia seriolae mycotic acid extraction and foam cell model induction method, and belongs to the crossing field of aquatic disease control and pathogenic biology, and the nocardia seriolae mycotic acid extraction and foam cell model induction method comprises the following steps: S1, mycotic acid extraction, and S2, foam cell model induction. A reliable material basis is provided for follow-up research from thallus culture to high-purity extract obtaining, when an induced foam cell model is constructed, detailed and normative operation steps cover macrophage separation, microsphere coating and co-culture detection, the in-vivo infection process can be accurately simulated, all links are closely connected, the steps are clear, repeatability is high, and the method is suitable for large-scale popularization and application. The method has the advantages that the method is convenient for other researchers to use for reference and verification, multi-dimensional research design can comprehensively explore the action mechanism of mycolic acid from cell and living body levels, deep understanding of nocardia seriolae nocardia pathogenesis is facilitated, and powerful theoretical basis and technical support are provided for prevention and control of fish nocardia diseases.

The invention provides an application of bazedoxifene in preparation of a medicine for promoting motor function recovery after spinal cord injury. Specifically, the invention provides an application of an active component, the active component is selected from bazedoxifene, or pharmaceutically acceptable salts thereof, or active derivatives thereof, and the active component is used for preparing a medicine or a kit for preventing and / or treating motor function recovery disorder after spinal cord injury. Or the active ingredient is used for preparing a preparation or a composition, and the preparation or the composition is used for inhibiting synaptic loss caused by lipid accumulation in foam cells.

The invention belongs to the technical field of basic medicine scientific research, and particularly relates to a method for rapidly constructing a mouse atherosclerosis model by using sorafenib. According to the method, the original molding period of 12 weeks or longer is shortened to 8 weeks, and the problem of long molding time is successfully solved; in addition, the atherosclerosis mouse model constructed by the method has a very remarkable atherosclerosis effect (the blood fat levels TC, TG and HDL-C are higher); the atherosclerotic aorta plaque area is larger, the blood vessel stenosis is more serious, and foam cells in the aortic valve are increased.

Provided are a thermoplastic elastomer (TPE) physically-foamed roll and a semi-continuous preparation method thereof. In the preparation method, the desorption of a high-pressure fluid is inhibited by controlling a solubility of the high-pressure fluid in a TPE roll and then subjecting the material to a quick freezing and gas-locking treatment at a specific temperature, and an impregnated roll can be stored at a low temperature for a long time or subjected to long-distance transportation, and can be stably subjected to continuous heating and foaming, which allows large-scale continuous production and is safe and environmentally-friendly. The present disclosure also provides a TPE physically-foamed roll prepared by the preparation method, and the TPE physically-foamed roll has a thickness of 0.1 mm to 3 mm, a density of 0.1 g / cm3 to 0.6 g / cm3, a foam cell size of 1 μm to 200 μm, and a Shore hardness of 20 C to 60 C.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses bovine serum albumin coated Prussian blue drug-loaded nanoparticles as well as a preparation method and application thereof, the drug-loaded nanoparticles are bovine serum albumin coated Prussian blue drug-loaded nanoparticles, and curcumin (Curcumin, Curr) is co-loaded to the surface of Prussian blue through hydrophobic interaction to obtain the drug-loaded nanoparticles. According to the drug-loaded nanoparticles provided by the invention, the accumulation and retention time of the drug in an atherosclerosis microenvironment can be remarkably prolonged. Passive targeting can be realized after intravenous injection administration, Prussian blue and curcumin are released at an inflammation part, Prussian blue clears active oxygen at the inflammation part by virtue of own enzyme-like activity, 808 nanometer laser irradiation is assisted, Prussian blue exerts a photothermal effect to increase excretion of lipid in foam cells, and in combination with the anti-inflammatory characteristic of curcumin, the anti-inflammatory effect of Prussian blue is improved. The treatment effect is improved.

The application discloses an endothelium-derived foam cell specific marker and application thereof, and belongs to the technical field of markers. The application proves that AKR1B1 is specifically highly expressed in endothelium-derived foam cells only, and can be used as a specific marker of eFCs by constructing cell and animal models and carrying out multi-level experiments in combination with clinical samples. Therefore, the application provides a tracer marker for revealing the dynamic evolution process of endothelial cell foam and the role of the endothelial cell foam in the progression of atherosclerosis, and provides a new theoretical basis and potential treatment target for precise diagnosis and targeted intervention of diseases.

The invention relates to a nanoparticle for atherosclerosis anti-aging diagnosis and treatment integration and a preparation method and application thereof, and the nanoparticle comprises an inner core KNZ which is a ZIF-8 nanoparticle loaded with a CAMKII-gamma inhibitor KN93; the surface of the KNZ is coated with a PDA coating to form pKNZ; l-arginine is modified on the surface of the pKNZ to form L-pKNZ; the L-pKNZ is chelated with Ga through a phenolic hydroxyl group to form Ga (at) L-pKNZ; the nanoparticles can be combined with a CAT-2 receptor on the surface of a macrophage through L-arginine to achieve active targeting, Zn is released through degradation of ZIF-8 to activate foam cell autophagy, a CAMKII-gamma / LXR-alpha / MerTK pathway is regulated through KN93 to enhance the interment effect of the macrophage, and in-situ reprogramming of an aging microenvironment in an atherosclerotic plaque is achieved; pET / CT imaging is achieved through Ga, and non-invasive monitoring is achieved.

This invention relates to the field of nanobubble technology, specifically to a macrophage membrane-modified cationic lipid nanobubble loaded with SHP-1 inhibitor, its preparation method, and its applications. This macrophage membrane-modified cationic lipid nanobubble loaded with SHP-1 inhibitor is constructed by using cationic lipid nanobubbles as the core carrier, electrostatically adsorbing and loading SHP-1 inhibitor, and further modifying it with a macrophage membrane. It not only possesses excellent physicochemical properties, a high cell membrane modification rate, and a high membrane protein retention rate, but also exhibits a high targeted uptake rate of M1 macrophages with an inflammatory phenotype in in vitro models. Furthermore, it promotes lipid efflux from foam cells and demonstrates good biocompatibility.